NCCN International Prognostic Index (NCCN-IPI) Calculator
Prognostic index for diffuse large B cell lymphoma
The NCCN-IPI applies to de novo diffuse large B cell lymphoma, at the time of diagnosis.
2. Determine risk group and prognosis
|NCCN-IPI score||Risk group||DLBCL 5 year OS1|
|0 - 1||Low||96%|
|2 - 3||Low-intermediate||82%|
|4 - 5||High-intermediate||64%|
The NCCN-IPI derives from multivariate analysis of survival of 1650 patients with newly-diagnosed de novo diffuse large B cell lymphoma treated between 2000 and 2010 at seven US National Comprehensive Cancer Network (NCCN) centers. The index was validated in an independent cohort of patients from the British Colombia Cancer Agency.1
Unlike the IPI, the NCCN-IPI derives from patients treated in the rituximab era. Although it uses the same clinical factors as the IPI, the NCCN-IPI includes additional age and LDH categories. In the reported training and internal and external validation cohorts, the NCCN-IPI provided better discrimination of high- and low-risk patients than did the IPI.2
- Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A HC et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014; 123: 837-42.
- A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. New Engl J Med 1993; 329: 987-994.